The field of lung cancer management is rapidly evolving because of the introduction of newer treatment modalities like stereotactic radiotherapy. The purpose of this focused issue on Stereotactic Radiotherapy and Lung Cancer is to discuss current paradigms and controversies on relevant and practical topics related to the use of lung SABR that face the modern oncologist in daily treatment decisions.
Preface
Turning up the stereo in lung cancer
Review Article
Stereotactic ablative radiation therapy for operable early-stage lung cancer—considerations and controversies
Practical considerations of lung stereotactic ablative radiotherapy in the developing world
Certainty versus practicality: when is histologic proof needed prior to stereotactic ablative radiotherapy for solitary pulmonary nodules?
Stereotactic ablative radiotherapy for central and ultra-central lung tumors
Response assessment and surveillance following stereotactic ablative radiotherapy for lung cancer
Is radiotherapy the missing link to enhancing the outcomes in non-small cell lung cancer patients treated with immunotherapy?
A proton primer to stereotactic lung radiotherapy
Stereotactic radiotherapy in previously treated lung cancers—what are the risks?
Stereotactic body radiotherapy for lung cancer in patients with interstitial lung disease
Disclosure:
The series “Stereotactic Radiotherapy and Lung Cancer” was commissioned by the editorial office, Therapeutic Radiology and Oncology without any sponsorship or funding. Alexander V. Louie and Joe Y. Chang served as the unpaid Guest Editors for the series.
